LeonardiCIKimballABPappKA. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet2008;371:1665–74, doi:10.1016/S0140-6736(08)60725-4.
2.
PappKALangleyRGLebwohlM. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet2008;371:1675–84, doi:10.1016/S0140-6736(08)60726-6.
3.
GordonKBFeldmanFRKooJY. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol2005;141:82–4, doi:10.1001/archderm.141.1.82.
4.
ZhuYHuCLuM. Population pharmacokinetic modelling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol2009;49:162–75, doi:10.1177/0091270008329556.
5.
GriffithsCEMStroberBvan de KerkhofP. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Medicine2010;362:118–28.
